Download full report with analyst certification and important disclosures
Nov 4 2020, 07:25 GMT
Amryt’s investor event yesterday (November 3rd) covered three main areas: (1) the Filsuvez phase III data; (2) regulatory timelines; (3) commercial plans. The Filsuvez data reinforce our view that it looks compelling from a regulatory and commercial standpoint. Regulatory timelines and commercial plans outlined were broadly as expected, with additional detail provided on future launches into markets outside the US and Europe. Furthermore, Amryt’s market assumptions suggest that there could be upside to our estimates.
Nov 4 2020, 07:25 GMT